Home

Exelixis, Inc. - Common Stock (EXEL)

37.42
-0.48 (-1.27%)
NASDAQ · Last Trade: Sep 1st, 2:49 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close37.90
Open37.78
Bid37.40
Ask37.42
Day's Range37.25 - 38.00
52 Week Range25.12 - 49.62
Volume2,590,286
Market Cap11.79B
PE Ratio (TTM)17.99
EPS (TTM)2.1
Dividend & YieldN/A (N/A)
1 Month Average Volume2,660,208

Chart

About Exelixis, Inc. - Common Stock (EXEL)

Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer. The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector. Read More

News & Press Releases

Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company’s drug discovery, translational research, product development and medical affairs activities.
By Exelixis, Inc. · Via Business Wire · August 29, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 29, 2025
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September:
By Exelixis, Inc. · Via Business Wire · August 27, 2025
Is the Market Bullish or Bearish on Exelixis?benzinga.com
Via Benzinga · August 26, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 25, 2025
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunitychartmill.com
Exelixis (EXEL) is a strong value investing candidate, trading below intrinsic value with a solid financial profile, high profitability, and strong growth prospects.
Via Chartmill · August 25, 2025
EXELIXIS INC (NASDAQ:EXEL) Emerges as a Top Growth at a Reasonable Price (GARP) Stockchartmill.com
EXELIXIS INC (EXEL) is a top GARP stock with strong growth, high profitability, and a reasonable valuation, making it a compelling investment opportunity.
Via Chartmill · August 22, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 21, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 17, 2025
Exelixis Inc (NASDAQ:EXEL): A Strong Growth Stock with Bullish Technical Setupchartmill.com
Exelixis (EXEL) is a strong growth stock with solid fundamentals—17.5% revenue growth, high profitability, and no debt—plus a bullish technical setup, signaling a potential breakout opportunity.
Via Chartmill · August 16, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 13, 2025
The Analyst Verdict: Exelixis In The Eyes Of 19 Expertsbenzinga.com
Via Benzinga · August 12, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 9, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 5, 2025
Exelixis EXEL Q2 2025 Earnings Call Transcriptfool.com
Via The Motley Fool · August 4, 2025
Novo Nordisk, United Parcel Service, And Moderna Are Among Top 10 Large Cap Losers Last Week (July 28-August 1): Are The Others In Your Portfolio?benzinga.com
Ten large-cap stocks, including Novo Nordisk and UPS, tumbled last week on weak earnings and guidance cuts.
Via Benzinga · August 3, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · August 1, 2025
EXELIXIS INC (NASDAQ:EXEL): A Strong Value Investment with Undervalued Potential and Solid Fundamentalschartmill.com
EXELIXIS (EXEL) is a top value stock with strong fundamentals—undervalued P/E, zero debt, high profitability, and solid growth. Ideal for value investors seeking quality at a discount.
Via Chartmill · July 30, 2025
Assessing Exelixis: Insights From 20 Financial Analystsbenzinga.com
Via Benzinga · July 29, 2025
AMD Rises To 1-Year Highs, Crude Eyes $68: What's Moving Markets Tuesday?benzinga.com
Risk appetite took a breather Tuesday, with major U.S. stock indices retreating modestly from record highs as investors braced for a pivotal stretch of earnings and macro events.
Via Benzinga · July 29, 2025
Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plansbenzinga.com
Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts shaped the update.
Via Benzinga · July 29, 2025
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · July 29, 2025
Exelixis Q2 Revenue Falls 11 Percentfool.com
Via The Motley Fool · July 28, 2025
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga.com
Via Benzinga · July 28, 2025
Curious about the stocks that are showing activity after the closing bell on Monday?chartmill.com
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · July 28, 2025